Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction

Abstract Aims Despite well‐established benefits of sacubitril/valsartan for cardiac reverse remodelling and the prognosis of patients with heart failure with reduced ejection fraction (HFrEF), there are some patients with limited therapeutic response, even with optimal therapy. We assessed the treat...

Full description

Bibliographic Details
Main Authors: Mi‐Gil Moon, In‐Chang Hwang, Wonsuk Choi, Goo‐Yeong Cho, Yeonyee E. Yoon, Jun‐Bean Park, Seung‐Pyo Lee, Hyung‐Kwan Kim, Yong‐Jin Kim
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:ESC Heart Failure
Subjects:
Sacubitril/valsartan
Angiotensin receptor‐neprilysin inhibitor
Heart failure with reduced ejection fraction
Reverse remodelling
Online Access:https://doi.org/10.1002/ehf2.13285

Internet

https://doi.org/10.1002/ehf2.13285

Similar Items